149 related articles for article (PubMed ID: 32277005)
1. Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.
Kotsopoulos J; McGee EE; Lozano-Esparza S; Garber JE; Ligibel J; Collins LC; Polyak K; Brown M; Narod S; Tamimi RM; Eliassen AH
Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1264-1270. PubMed ID: 32277005
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.
Fortner RT; Sarink D; Schock H; Johnson T; Tjønneland A; Olsen A; Overvad K; Affret A; His M; Boutron-Ruault MC; Boeing H; Trichopoulou A; Naska A; Orfanos P; Palli D; Sieri S; Mattiello A; Tumino R; Ricceri F; Bueno-de-Mesquita HB; Peeters PH; Van Gils CH; Weiderpass E; Lund E; Quirós JR; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Dorronsoro M; Key T; Khaw KT; Rinaldi S; Dossus L; Gunter M; Merritt MA; Riboli E; Kaaks R
BMC Med; 2017 Feb; 15(1):26. PubMed ID: 28173834
[TBL] [Abstract][Full Text] [Related]
3. Serum osteoprotegerin levels and mammographic density among high-risk women.
Moran O; Zaman T; Eisen A; Demsky R; Blackmore K; Knight JA; Elser C; Ginsburg O; Zbuk K; Yaffe M; Narod SA; Salmena L; Kotsopoulos J
Cancer Causes Control; 2018 Jun; 29(6):507-517. PubMed ID: 29679262
[TBL] [Abstract][Full Text] [Related]
4. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Sarink D; Schock H; Johnson T; Overvad K; Holm M; Tjønneland A; Boutron-Ruault MC; His M; Kvaskoff M; Boeing H; Lagiou P; Papatesta EM; Trichopoulou A; Palli D; Pala V; Mattiello A; Tumino R; Sacerdote C; Bueno-de-Mesquita HBA; van Gils CH; Peeters PH; Weiderpass E; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Amiano P; Khaw KT; Travis R; Dossus L; Gunter M; Rinaldi S; Merritt M; Riboli E; Kaaks R; Fortner RT
Cancer Prev Res (Phila); 2017 Sep; 10(9):525-534. PubMed ID: 28701332
[TBL] [Abstract][Full Text] [Related]
5. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Odén L; Akbari M; Zaman T; Singer CF; Sun P; Narod SA; Salmena L; Kotsopoulos J
Oncotarget; 2016 Dec; 7(52):86687-86694. PubMed ID: 27893411
[TBL] [Abstract][Full Text] [Related]
6. Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.
Eliassen AH; Zeleniuch-Jacquotte A; Rosner B; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2016 May; 25(5):854-60. PubMed ID: 26961996
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
Sarink D; Schock H; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Arveux P; Fournier A; Kvaskoff M; Boeing H; Karakatsani A; Trichopoulou A; La Vecchia C; Masala G; Agnoli C; Panico S; Tumino R; Sacerdote C; van Gils CH; Peeters PHM; Weiderpass E; Agudo A; Rodríguez-Barranco M; Huerta JM; Ardanaz E; Gil L; Kaw KT; Schmidt JA; Dossus L; His M; Aune D; Riboli E; Kaaks R; Fortner RT
BMC Cancer; 2018 Oct; 18(1):1010. PubMed ID: 30348163
[TBL] [Abstract][Full Text] [Related]
8. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
[TBL] [Abstract][Full Text] [Related]
9. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
10. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
Xie J; Tworoger SS; Franke AA; Terry KL; Rice MS; Rosner BA; Willett WC; Hankinson SE; Eliassen AH
Breast Cancer Res Treat; 2013 Jun; 139(3):801-9. PubMed ID: 23760859
[TBL] [Abstract][Full Text] [Related]
11. Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort.
Sarink D; Yang J; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Fournier A; Mancini FR; Kvaskoff M; Boeing H; Trichopoulou A; Karakatsani A; Valanou E; Agnoli C; Sacerdote C; Masala G; Mattiello A; Tumino R; Van Gils CH; Skeie G; Gram IT; Weiderpass E; Lujan-Barroso L; Petrova D; Santiuste C; Quirós JR; Barricarte A; Amiano P; Travis RC; Gunter M; Dossus L; Christakoudi S; Kaaks R; Fortner RT
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1746-1754. PubMed ID: 31292137
[TBL] [Abstract][Full Text] [Related]
12. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
[TBL] [Abstract][Full Text] [Related]
15. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
[TBL] [Abstract][Full Text] [Related]
16. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II.
Eliassen AH; Spiegelman D; Hollis BW; Horst RL; Willett WC; Hankinson SE
Breast Cancer Res; 2011 May; 13(3):R50. PubMed ID: 21569367
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
18. Prediction of subclinical atherosclerosis by serum osteoprotegerin in premenopausal women with systemic lupus erythematous: correlation of osteoprotegerin with monocyte chemotactic protein-1.
Park YJ; Shin YJ; Kim WU; Cho CS
Lupus; 2014 Mar; 23(3):236-44. PubMed ID: 24531425
[TBL] [Abstract][Full Text] [Related]
19. Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses' health studies.
Sisti JS; Lindström S; Kraft P; Tamimi RM; Rosner BA; Wu T; Willett WC; Eliassen AH
Breast Cancer Res Treat; 2015 Jun; 151(2):415-25. PubMed ID: 25917867
[TBL] [Abstract][Full Text] [Related]
20. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II.
Wang J; Eliassen AH; Spiegelman D; Willett WC; Hankinson SE
Cancer Causes Control; 2014 Jul; 25(7):819-27. PubMed ID: 24748579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
